Back
Eagle Materials 10K Form
Buy
58
EXP
Eagle Materials
Last Price:
290.00
Seasonality Move:
12.71%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-10-26 | 10Q | EXP/Eagle Materials Quarterly |
2023-07-27 | 10Q | EXP/Eagle Materials Quarterly |
2023-01-26 | 10Q | EXP/Eagle Materials Quarterly |
2022-10-26 | 10Q | EXP/Eagle Materials Quarterly |
2022-07-28 | 10Q | EXP/Eagle Materials Quarterly |
2022-01-27 | 10Q | EXP/Eagle Materials Quarterly |
Receive EXP News And Ratings
See the #1 stock for the next 7 days that we like better than EXP
EXP Financial Statistics
Sales & Book Value
Annual Sales: | $2.26B |
---|---|
Cash Flow: | $166.79M |
Price / Cash Flow: | 21.38 |
Annual Sales: | $42.69 |
Price / Book: | 6.75 |
Profitability
EPS (TTM): | 14.16000 |
---|---|
Net Income (TTM): | $483.6M |
Gross Margin: | $685.32M |
Return on Equity: | 35.93% |
Return on Assets: | 16.21% |
Eagle Materials Earnings Forecast
Key Eagle Materials Financial Ratios
- The Gross Profit Margin over the past 31 years for EXP is 30.33%.
- The Selling, General & Administrative Expenses for EXP have been equal to 2.65% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 9.07% of Operating Income.
- The Net Earning history of EXP is 21.14% of Total Revenues.
- Per Share Earnings over the last 31 years have been positive in 22 years.
Eagle Materials Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Construction Materials |
Sector: | Materials |
Current Symbol: | EXP |
CUSIP: | 26969P |
Website: | eaglematerials.com |
Debt
Debt-to-Equity Ratio: | 0.75 |
---|---|
Current Ratio: | 2.34 |
Quick Ratio: | 1.1 |
Price-to-Earnings
Trailing P/E Ratio: | 21.18 |
---|---|
Forward P/E Ratio: | 17.04 |
EXP Technical Analysis vs Fundamental Analysis
Buy
58
Eagle Materials (EXP)
is a Buy
Is Eagle Materials a Buy or a Sell?
-
Eagle Materials stock is rated a Buy
The current Eagle Materials [EXP] share price is $288.25. The Score for EXP is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.